|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 肝素诱发的血小板减少治疗指南显示文摘推荐总结
所有患者使用任何一种肝素时,用药开始都要计数血小板。
在100天之内曾接受肝素治疗的患者,需要计数血小板用药前及用药24小时后血小板数目。
所有使用普通肝素的患者,在用药的4~14天之间需要隔日计数血小板。 | Keeling D Davidson S Watson H 曹丽娟(编译) 王兆钺(审校) | 2006 | 国际输血及血液学杂志2006，29，6： | 5 |
| 2 | Fondaparinux预防老年急性内科患者发生静脉血栓形成的效果与安全性:随机安慰剂对照研究显示文摘目的:观察 Fondaparinux 对具有中高度静脉血栓发生危险的老年急性内科住院患者的抗凝效果与安全性。设计:双盲随机安慰剂对照研究。背景:8个国家的35个中心。参与者:849例≥60岁内科患者,住院原因分别为充血性心力衰竭、慢性肺病合并急性呼吸系统疾患、急性炎症性或感染性疾病,预期至少住院4天以上。干预:2.5 mg Fondaparinux 或安慰剂,每天1次皮下注射,持续6~14天。观察指标:主要指标为静脉血栓形成(治疗后15天内采用双侧静脉造影检查)及有症状的静脉血栓;次要指标为死亡与出血。患者随访时间为1个月。结果:Fondaparinux 治疗组425例患者和安慰剂组414例患者接受了安全性分析(10例未治疗)。644例患者(75.9%)可接受主要指标分析。静脉血栓检出率在 Fondaparinux 治疗组为5.6%(18/321),安慰剂组为10.5%(34/323),相对危险减少46.7%(95% CI 7.7%~69.3%)。安慰剂组5例患者发生有症状的静脉血栓,Fondaparinux治疗组无患者发生有症状的静脉血栓(P=0.029)。两组均有1例(0.2%)患者发生严重出血。随访结束时,安慰剂组、Fondaparinux 治疗组分别死亡25(6.0%)、14(3.3%)例患者。结论:Fondaparinux 可有效预防急性内科老年患者无症状性及有症状的静脉血栓。严重出血几率两组相似。 | Alexander T Cohen Bruce L Davidson Alexander S Gallus Michael R Lassen Martin H Prins Witold Tomkowski Alexander G G Turpie Jan F M Egberts Anthonie W A Lensing 石汉平(译) 王深明(校) | 2006 | 英国医学杂志中文版2006，9，5： | 3 |
| 3 | Measuring water quality and predicting well impairment显示文摘 | Barkman J H Davidson D H | 1972 | J Petrol Technol1972，24，6： | 2 |
| 4 | Anticipatory Activation in the Amygdala and Anterior Cingulate in Generalized Anxiety Disorder and Prediction of Treatment Response显示文摘 | Nitschke Jack B Sarinopoulos Issidoros Oathes Desmond J Johnstone Tom Whalen Paul J Davidson Richard J Kalin Ned H | 2009 | The American Journal of Psychiatry2009，，3： | 2 |
| 5 | Comparison of the efficacy and safety of rosuvastatin versus atorvastatin , simvastatin , and pravastatin across doses (STELLAR * * STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)显示文摘 | Peter H Jones Michael H Davidson Evan A Stein Harold E Bays James M McKenney Elinor Miller Valerie A Cain James W Blasetto | 2003 | The American Journal of Cardiology2003，，2： | 2 |
| 6 | Phosphorylation-dependent regulation of T-cell activation by PAG/CBP,a lipid raft-associated transmembrane adaptor 显示文摘 | Davidson D Dominique H Bakinowski D | 2003 | Mol Cell Biol2003，23，6： | 1 |
| 7 | Erythroid transcription factor NF-E2 is a haematopoietic-specific basic-leucine zipper protein显示文摘 | ERDJUMENT-BROMAGE H DAVIDSON M B | 1993 | Nature1993，362，6422： | 1 |
| 8 | Diffusion and chemical activity of Zr-Sn and Zr-Ti systems 显示文摘 | ZEE R H WATTERS J F DAVIDSON R D | 1986 | Physical Review B1986，34，10： | 1 |
| 9 | Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma 显示文摘 | Xu H J Quinlan D C Davidson A G | 1994 | J Natl Cancer Inst1994，86，9： | 1 |
| 10 | Effects of atracurium on intraocuiar pressure, eye position, and blood pressure in eucapnic and phyocapnic isoflurane-anes- thetized dogs 显示文摘 | Mcmurphy R M Davidson H J Hodgson D S | 2004 | Am J Vet Res2004，65，5： | 1 |
| 11 | Nitrogen leac- hing in Berrndagrass turf显示文摘 | Synder G H Burt E O Davidson J M | 1981 | Turfgrass Society1981，107，： | 1 |
| 12 | Characterization of bromated-reducing bacterial isolates and their potential for drinking water treatment 显示文摘 | Davidson A N Chee-Sanford J Lai H Y | 2011 | Water Research2011，45，10： | 1 |
| 13 | Signalling by fibroblast growth factor receptor 3 and parathyroid hormone-related peptide coordinate cartilage and bone development 显示文摘 | AMIZUKA N DAVIDSON D LIU H | 2004 | Bone2004，34，1： | 1 |
| 14 | Econometric Modeling of the Aggregate Time-Series Re- lationship between Consumers' Expenditure and Income in the United Kingdom显示文摘 | DAVIDSON J E H HENDRY D SRBA F | 1978 | The Economic Journal1978，88，12： | 1 |
| 15 | Kringle domains of human angostatin 显示文摘 | Cao Y H Richard W J Davidson D | 1996 | The Journal of Biological Chemistry1996，271，29： | 1 |
| 16 | Econometric modeling of the time-series relationship between consumers' expenditure and income in the United Kingdom 显示文摘 | Davidson J E H Hendry D F Srba F Yeo S | 1978 | Economic Journal1978，，88： | 1 |
| 17 | Efficacy and safety of simvastati n 80 mg /day in hypercholesterolemic patients显示文摘 | Evan A Stein Michael H Davidson | 1998 | Am J Cardiol1998，82，： | 1 |
| 18 | Guidelines on the diagnosis and management of heparin-induced thrombocytopenia:2nd ed显示文摘 | Watson H Davidson S Keeling D | 2012 | Br J Haematol2012，159，5： | 1 |
| 19 | Overview of prevention and treatment of atherosclerosis with lipid altering therapy for pharmacy directors显示文摘 | Davidson M H | | 0，，10： | 1 |
| 20 | Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvasta- tin, and pravastatin across doses (STELLAR Trial ) 显示文摘 | JONES P H DAVIDSON M H STEIN E A | 2003 | Am J Cardiol2003，92，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员